利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.02 秒)

    Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
    2.
    发明授权
    Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate 失效
    使用甲磺酸伊马替尼治疗费城阳性白血病的方法

    公开(公告)号：US08697702B2

    公开(公告)日：2014-04-15

    申请号：US13129903

    申请日：2009-11-30

    申请人： Yanfeng Wang ,  Thea Kalebic ,  Timothy P Hughes ,  Deborah White

    发明人： Yanfeng Wang ,  Thea Kalebic ,  Timothy P Hughes ,  Deborah White

    IPC分类号： A61K31/497

    CPC分类号： A61K31/506

    摘要： The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Phi+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of (a) administering a predetermined fixed amount of Imatinib as a free base or in the form of a pharmaceutically acceptable salt thereof to the human patient, (b) collecting at least one blood sample from the patient, e.g. within the first 12 months of treatment, (c) determining the plasma trough level (Cmin) of Imatinib, (d) determining the OCT-1 Activity in the blood sample, and (e) adjusting the dose of Imatinib applied to the individual patient in a manner that an Imatinib Cmin value is achieved in the patient of at least 800 ng/mL, if in step (c) an Imatinib Cmin value of less than 800 ng/mL is found and in step (d) an OCT-1 Activity is found below 6.0 to 10.0 ng/200,000 cells.

    摘要翻译： 本发明涉及在人类患者群体中治疗特定慢性骨髓性白血病（CML）中的费城阳性白血病（Ph +白血病）的方法。 更具体地，本发明涉及在患有Ph +白血病的人类患者中治疗Ph +白血病（例如CML或Phi + ALL）的方法，包括以下步骤：（a）施用预定的固定量的伊马替尼作为游离碱或 其药学上可接受的盐的形式提供给人类患者，（b）从患者收集至少一种血液样品， 在治疗的头12个月内，（c）确定伊马替尼的血浆谷值（Cmin），（d）确定血液样品中的OCT-1活性，和（e）调整施用于个体患者的伊马替尼剂量 如果在步骤（c）中发现伊马替尼Cmin值小于800ng / mL，并且在步骤（d）中OCT-1 活性发现低于6.0至10.0ng / 20万个细胞。

    Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate
    3.
    发明申请
    Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate 失效
    使用甲磺酸伊马替尼治疗费城阳性白血病的方法

    公开(公告)号：US20110224224A1

    公开(公告)日：2011-09-15

    申请号：US13129903

    申请日：2009-11-30

    申请人： Yanfeng Wang ,  Thea Kalebic ,  Timothy Peter Hughes ,  Deborah White

    发明人： Yanfeng Wang ,  Thea Kalebic ,  Timothy Peter Hughes ,  Deborah White

    IPC分类号： A61K31/506 ,  A61P35/02

    CPC分类号： A61K31/506

    摘要： The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Ph+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of(a) administering a predetermined fixed amount of Imatinib as a free base or in the form of a pharmaceutically acceptable salt thereof to the human patient,(b) collecting at least one blood sample from the patient, e.g. within the first 12 months of treatment,(c) determining the plasma trough level (Cmin) of Imatinib,(d) determining the OCT-1 Activity in the blood sample, and(e) adjusting the dose of Imatinib applied to the individual patient in a manner that an Imatinib Cmin value is achieved in the patient of at least 800 ng/mL, if in step (c) an Imatinib Cmin value of less than 800 ng/mL is found and in step (d) an OCT-1 Activity is found below 6.0 to 10.0 ng/200,000 cells.

    摘要翻译： 本发明涉及在人类患者群体中治疗特定慢性骨髓性白血病（CML）中的费城阳性白血病（Ph +白血病）的方法。 更具体地，本发明涉及在患有Ph +白血病的人类患者中治疗Ph +白血病（例如CML或Ph + ALL）的方法，包括以下步骤：（a）施用预定的固定量的伊马替尼作为游离碱或 其药学上可接受的盐的形式提供给人类患者，（b）从患者收集至少一种血液样品， 在治疗的头12个月内，（c）确定伊马替尼的血浆谷值（Cmin），（d）确定血液样品中的OCT-1活性，和（e）调整施用于个体患者的伊马替尼剂量 如果在步骤（c）中发现伊马替尼Cmin值小于800ng / mL，并且在步骤（d）中OCT-1 活性发现低于6.0至10.0ng / 20万个细胞。

    Suppression of HIV expression by organic thiophosphate
    5.
    发明授权
    Suppression of HIV expression by organic thiophosphate 失效
    有机硫代磷酸盐抑制HIV表达

    公开(公告)号：US5824664A

    公开(公告)日：1998-10-20

    申请号：US37633

    申请日：1993-03-26

    申请人： Philip S. Schein ,  Thea Kalebic

    发明人： Philip S. Schein ,  Thea Kalebic

    IPC分类号： A61K31/66 ,  A01N57/10 ,  A01N57/00 ,  A61K31/13

    CPC分类号： A61K31/66 ,  A61K31/70

    摘要： Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF.alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.

    摘要翻译： 通过向受试者单独或与另一种抗艾滋病毒或抗艾滋病药物组合施用有机硫代磷酸盐来治疗慢性HIV感染。 有机硫代磷酸酯优选为WR 151327，具有抗氧化和自由基清除活性的化合物或其功能衍生物或类似物。 WR 151327抑制由细胞因子如TNFα和GM-CSF介导的慢性感染细胞中的HIV表达的诱导。 还公开了包含至少一种有机硫代磷酸酯与一种或多种抗艾滋病毒或抗艾滋病药物组合的药物组合物。